The financials
Veracyte, Inc. by the numbers
Veracyte, Inc. (VCYT) reported revenue of $139M in Q1 2026 (quarter ended March 31, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $29M (21% of revenue). For the full year FY2025, revenue was $517M (+16% year on year) and net income $66M. Its largest product in 2026-Q1 was Testing at $135M, 97% of the disclosed total, just ahead of Testing Other at 3.0%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $139M | $114M | +21% |
| Gross profit | $101M | $80M | +27% |
| Operating income | $23M | $2.9M | +680% |
| Net income | $29M | $7.0M | +307% |
| Diluted EPS | $0.35 | $0.09 | +289% |
| Product | Revenue | Share |
|---|---|---|
| Testing | $135M | 97% |
| Testing Other | $4.2M | 3.0% |
| Biopharmaceutical And Other Biopharmaceutical | $301K | 0.2% |
| Biopharmaceutical And Other | $301K | 0.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $139.9M (+6.9%)
Testing Other grew +950% year on yearBiopharmaceutical And Other Contract Manufacturing And Testing -100% year on year
Segment Latestquarter on quarteryear on year
- Testing$135.1M$135.1MQoQ +5.7%year on year +26%+5.7%+26%
- Testing Other$4.2M$4.2MQoQ +180%year on year +950%+180%+950%
- Biopharmaceutical And Other Biopharmaceutical$301.0K$301.0KQoQ -53%year on year -87%-53%-87%
- Biopharmaceutical And Other$301.0K$301.0KQoQ -63%year on year -92%-63%-92%
- Biopharmaceutical And Other Contract Manufacturing And Testing$0.00$0.00QoQ -100%year on year -100%-100%-100%
Diagnostics & Research
Ranks #19 of 29 by Smart Score